Acquired Myopathies

Published on 03/03/2015 by admin

Filed under Neurology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 3 (1 votes)

This article have been viewed 4999 times

76 Acquired Myopathies

Myopathies are disorders that adversely affect muscle function (Greek “myo” = muscle and “pathy” = suffering). Insights from molecular biology are changing the traditional classification of muscle disorders and opening new areas of investigation.

Clinical Vignette

The patient is a 33-year-old woman who presents with a 6-month history of difficulty climbing stairs. Recently she noticed she could not climb the 10 steps from her basement. She has also developed problems picking up jars from shelves of tall cabinets as well as inability to keep her hands over her head to brush her hair. Her ability to swallow has been fine and she has not experienced any shortness of breath. Her examination was significant for bilateral weakness of her hip flexors (iliopsoas), deltoids, biceps, and triceps. Muscle stretch reflexes were diminished but present. Sensory examination was normal.

Serum creatine kinase (CK) was increased to 1200 IU/L (six times normal). Electromyography (EMG) demonstrated normal nerve conduction studies. However, needle examination was abnormal, with large numbers of short-duration, low-amplitude, polyphasic motor unit potentials associated with scattered fibrillation potentials and complex repetitive discharges.

Comment: This patient’s presentation is typical for a myopathic process with the clinical picture of evolving proximal weakness, elevated serum CK, and abnormal EMG.

The common nongenetically determined myopathies are classified into those having a primary inflammatory process, an underlying endocrinopathy, a toxic pathophysiology, or an underlying associated systemic disorder. Much less commonly, a few infectious agents, such as trichinosis, may lead to a primary myopathy. Myopathies typically present with symmetric symptoms and signs of muscle weakness affecting the proximal limbs and paraspinal musculature (Fig. 76-1). Asymmetric, distal, generalized, or regional patterns of weakness also occur in certain distinct myopathies such as inclusion body myositis (IBM). Less commonly, ventilatory muscles or cardiac muscles are primarily affected. Myopathies occasionally present with periodic weakness, exercise-induced muscle pain, or stiffness.

Muscle weakness is a common defining feature of a variety of peripheral motor unit disorders. Myopathies are included in the same differential diagnosis as neuromuscular transmission disorders, motor neuron disease, as well as rare demyelinating polyneuropathies. Muscle stretch reflexes are generally normal, and sensation is usually unaffected in primary myopathies. The presence of certain distinguishing clinical features may help in the diagnosis of a myopathy. These include the pattern of weakness (e.g., presence of ptosis, ophthalmoparesis, ventilatory muscle weakness, scapular winging, and head drop) or other clinical features (e.g., contractures, skeletal dysmorphisms, calf hypertrophy, myotonia, cardiac involvement, or subtle to marked dermatologic changes). Another very important diagnostic determinant is an assessment of the clinical temporal profile (e.g., the rate of progression), any history of a relapsing (periodic) weakness, diurnal variation, and symptoms that occur only with exertion. Other important factors include genetic predisposition, medication and toxin exposure, and other organ system involvement.

Diagnostic Approach

Patients who present with symptoms of myalgia and muscle weakness with a normal muscle strength examination and with normal or mildly elevated serum creatine kinase (CK) levels are common in clinical practice. Such patients are diagnostically and therapeutically challenging. Definable myopathic disorders are uncommon in patients who present with muscle pain, fatigue, or exercise intolerance in the absence of objective clinical, laboratory, or electrophysiologic abnormalities.

Laboratory Evaluation

The serum CK is characteristically increased in many myopathies; this may vary from a 2- to 50-fold increase, although in most myopathies CKs are usually in the 500–5000 IU/mL range (Fig. 76-2). When this enzyme is abnormally elevated, its serum levels do not closely parallel disease severity or activity. Serum aldolase levels are also frequently elevated in myopathies; its increase generally parallels the increase in CK, although many clinical neuromuscular specialists do not routinely order an aldolase level. However on occasion it may be elevated with a normal CK as illustrated in the Cushing syndrome vignette reported later in this chapter.

An increased CK level is a nonspecific finding vis-à-vis the diagnosis of myopathies. Other motor unit disorders (such as motor neuron disease, amyotrophic lateral sclerosis, or spinal muscular atrophy) and systemic processes (particularly myxedema) are commonly associated with increased CK of two to five times normal levels. Conversely, the serum CK can be normal in certain patients with DM and IBM.

Patients with persistently increased CK levels sometimes associated with muscle pain but without clinically demonstrable weakness, family history, or exposure to potentially myotoxic substances are classified as having hyperCKemia. Despite thorough clinical and laboratory examination, it is often difficult to assign a specific pathophysiologic mechanism to this finding. HyperCKemia is often an elusive clinical challenge. However, it is important to emphasize that although no diagnosis per se is defined, the finding of hyperCKemia deserves serious consideration. Such individuals are at an increased risk of developing malignant hyperthermia (MH) if they require surgery under general anesthesia. Certain induction agents, particularly the halogenated ones, namely halothane, are particularly prone to inducing this life-threatening complication in patients with hyperCKemia. Therefore, we suggest that our hyperCKemia patients wear a MedAlert bracelet to always call the attention of anesthesiologists to this finding and thus potentially prevent an episode of MH (Fig. 76-3).

Serum aspartate and alanine aminotransferases (AST and ALT) are frequently elevated in many myopathies as these enzymes are released by diseased muscle. Rarely some patients with clinically unsuspected myopathies undergo unnecessary evaluation for liver disease when AST and ALT elevations are found and the CK has not been checked. Other liver function studies (e.g., gamma glutamyl transpeptidase and prothrombin time) are normal, providing another clue to the probability of a primary skeletal muscle rather than a hepatic disorder.

Routine biochemistry and hematologic laboratory tests are usually normal in patients with myopathy. Serum potassium levels should be checked to exclude Addison disease with hyperkalemia. Various muscle disorders characterized by episodic periodic paralysis may sometimes have either hypokalemia or hyperkalemia if they are tested during the overt period of paralysis. However, these patients most often have normal potassium values if tested between episodes of weakness. Serum markers of inflammation such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) may be elevated in some acute myopathies. Thyroid function evaluation (serum TSH levels) must be considered in all patients presenting with an acute or chronic myopathy. Both hypothyroidism and rarely hyperthyroidism may present with primary muscle involvement. Appropriate endocrine evaluation is necessary in myopathic patients when a more obvious diagnosis is not apparent. These also include pituitary adrenal disorders such as Cushing syndrome or Addison disease, and very rarely hyperparathyroidism. In certain ethnic groups, for example, Chinese and Hispanics, thyrotoxicosis may be associated with hypokalemia and a proximal myopathy resembling periodic paralysis.

The serum myositis-specific and myositis-associated antibodies are other testing parameters that are useful in the evaluation of some patients with a myopathy. However, as these are present in fewer than half of all patients with polymyositis and dermatomyositis, routine serologic testing for these antibodies is of limited use. The presence of anti-Jo-1 (antibody to histidyl t-RNA synthetase) antibodies suggests potential end organ comorbidity, for example, interstitial lung disease (Fig. 76-4). Signal recognition particle antibodies are most often associated with necrotizing myopathies and may suggest a poor treatment response.

Sometimes polymyositis is associated with an underlying connective tissue disorder. In those patients, serologic markers for the underlying disease may be positive. These include antinuclear antibody (ANA), and/or rheumatoid factor. On occasion, the presence of these antibodies can aid in the diagnosis of the occasional patient for whom the history is not definitive. This is especially so when there is diagnostic confusion between the possibility of an acquired inflammatory myopathy and a genetically determined dystrophy. When polymyositis and, less commonly, dermatomyositis is associated with other collagen-vascular diseases, the combination is referred to as an overlap syndrome. Systemic lupus erythematosus (SLE), systemic sclerosis, rheumatoid arthritis, and Sjögren syndrome may have weakness as a component of their myriad symptoms and signs. In these cases, muscular weakness exceeds what arthritis alone can account for. They are characterized by elevated titers of anti–U1/U2-ribonucleoprotein antibodies, PM-Scl antibodies or SSA antibodies in scleroderma, Sjögren syndrome, SLE, or mixed connective tissue disease. Dermatomyositis is rarely associated with other collagen-vascular diseases, with the exception of scleroderma.

Paraneoplastic antibody evaluation may occasionally be helpful in the differential diagnosis of proximal weakness. This is particularly so in patients with Lambert–Eaton myasthenic syndrome (LEMS) who often present with symptoms emulating a myopathy. These individuals have elevated levels of voltage-gated calcium channel antibodies. This finding, in addition to the classic EMG nerve conduction studies typically seen in LEMS, is very specific for this diagnosis. In addition, anti-Hu antibodies may be positive in patients with myopathy associated with small cell lung cancer.

Immunofixation to look for the presence of serum monoclonal protein is necessary in certain instances if either amyloid myopathy or sporadic late-onset nemaline myopathy (SLONM) is in the differential diagnosis. Approximately 20% of patients with IBM also have a MGUS. Appropriate endocrine evaluation is necessary in myopathic patients when a more obvious diagnosis is not apparent.

Vitamin D levels are also important. Rarely hypovitaminosis D may present with a myopathy. Similarly, patients with primary or secondary osteomalacia may present with proximal weakness. Elevated serum calcium and alkaline phosphatase values may point toward these underrecognized disorders.

Electromyography

EMG evaluation of patients with suspected myopathies is important (Fig. 76-5, and see Fig. 76-2). Results of routine nerve conduction studies are normal in myopathies, with the exception of diminished compound muscle action potential amplitudes in more severe disorders. The primary EMG abnormalities in the myopathies are classically found at the time of the needle examination. Classic findings of a myopathy include the presence of abnormally low amplitude, short duration, and polyphasic motor unit potentials (MUPs). It is typical for these patients to have both an early recruitment and increased numbers of MUPs early on in the muscle activation for a given effort. Destruction of myofibrils or muscle membrane results in abnormal insertional activity, particularly fibrillation potentials and complex repetitive discharges. Inflammatory myopathies, several dystrophies, and various myotonic muscle disorders may be distinguished by the presence of myotonic potentials on needle EMG.

Concomitantly, EMG helps to exclude disorders that affect other anatomic sites within the peripheral motor unit, particularly those with symmetric proximal weakness mimicking a myopathy. These include motor neuron disorders, such as amyotrophic lateral sclerosis, spinal muscular atrophy type 3, chronic inflammatory demyelinating polyneuropathies, neuromuscular transmission disorders (particularly Lambert–Eaton myasthenic syndrome), and myasthenia gravis. Results of EMG are often normal in the various endocrine, mitochondrial, and congenital myopathies.

Muscle Biopsy

Muscle biopsy is the definitive diagnostic tool for many myopathies (Fig. 76-6). The selection of the biopsy site is important; muscles that are unaffected, that are severely affected (are at end stage), or have been recently subjected to EMG evaluation should be avoided. Muscles commonly biopsied include the vastus lateralis, deltoid, and biceps brachii. The gastrocnemius muscle is often avoided due to the possibility of incidentally discovered neurogenic atrophy. The upper lumbosacral muscles, thoracic paraspinal muscles, such as the multifidus, and much less commonly the cervical paraspinal muscles provide an alternative site for biopsy. On reflection one recognizes that these muscles are indeed the most proximal ones and thus more prone to show early changes of an active myopathic process.

The muscle biopsy specimen per se is divided into separate aliquots for formalin fixation, paraffin embedding, and immediate freezing. The formalin-fixed piece is stained with hematoxylin and eosin (H and E) because this permits a rapid means for initial evaluation. This is especially useful for identifying inflammatory myopathies where such a diagnosis offers the potential for successful therapeutic intervention. Frozen specimens are best for other stains, including nicotinamide adenosine dinucleotide dehydrogenase (NADH), modified Gomori trichrome, adenosine triphosphatase, and lipid and glycogen stains (Fig. 76-7 and see Fig. 76-5).

Muscle biopsy specimens are also subjected to biochemical analysis, mutational analysis, and electron microscopy, when these techniques are indicated. Inherited myopathies, such as the various muscular dystrophies, are evaluated by immunohistochemical stains, immunoblotting; testing is available for calpain, caveolin, dysferlin, the dystroglycans, dystrophin, laminin-2 (formerly merosin), and the sarcoglycans.

Specific Inflammatory Myopathic Disorders

There are three primary inflammatory disorders: polymyositis, dermatomyositis, and inclusion body myositis. Necrotizing myopathies are usually not considered to be inflammatory myopathies although there is some evidence that they may respond to immune-modifying treatment.

Polymyositis

This inflammatory myopathy is seen mainly in adults and presents subacutely usually over a period of several weeks to a few months. Clinically an important means for distinguishing polymyositis (PM) from dermatomyositis (DM) is the absence of skin involvement in PM. However, DM may also rarely present without skin involvement (sine dermatitis). Various criteria have been proposed to make a definitive diagnosis of PM. Usually PM patients present with symmetric proximal weakness, involving the upper and lower extremities. Mild dysphagia, myalgia, and systemic symptoms, such as polyarthritis, may accompany the weakness. Rarely patients may present with either a clinically isolated head drop, or respiratory muscle weakness. Acid maltase deficiency, glycogen storage disease type II, needs to be considered in those individuals presenting primarily with pulmonary manifestations.

EMG is often abnormal and may show characteristic findings, myopathic motor units, and increased insertional activity, with fibrillation potentials and complex repetitive discharges. Laboratory studies reveal an elevated CK level. Muscle biopsy demonstrates perimysial and endomysial inflammatory infiltrate with CD8+ T cells invading nonnecrotic muscle fibers (see Fig. 76-5). Interstitial lung disease can be seen in 10–20% of patients with PM and may be associated with positive anti-Jo1 antibody. Cardiac involvement (cardiomyopathy and congestive heart failure) is common, although the incidence of these associated conditions is unknown.

Dermatomyositis

Dermatomyositis (DM) is also seen in both children and adults. Proximal weakness develops insidiously over weeks. The characteristic rash may accompany or precede the myopathy (see Fig. 76-1). The rash is present over the exposed areas of the face, neck, and arms. Other dermatologic manifestations include heliotrope rash over the eyelids and erythematous rash over the knuckles, known as Gottron papules (Fig. 76-1, bottom). Nail bed examination will often demonstrate capillary telangiectasia. Occasional DM patients never develop this classic rash; here the differential diagnosis from PM is made on the classic pathologic findings of perifascicular atrophies in the muscle biopsy. In contrast, some patients present with the classic DM rash but paradoxically have no signs of a clinical myopathy (amyopathic DM). Other systemic manifestations include calcinosis, dysphagia, cardiomyopathy, and interstitial lung disease (ILD) (see Fig. 76-4). As in PM, ILD may be associated with positive anti-Jo 1 antibodies in some patients.

Dermatomyositis in adults may be associated with underlying malignancy. The cumulative incidence rate of malignancy varied from 20% at 1-year post DM diagnosis to approximately 30% five years after the diagnosis of DM. Adult patient should undergo evaluation for a possible underlying malignancy. The intensity of diagnostic evaluation for a potential occult cancer is determined individually. Factors that point to a higher likelihood of a paraneoplastic relationship include age at diagnosis >52 years, a rapid onset of skin and/or muscular symptoms, the presence of skin necrosis or periungual erythema, and a low baseline level of complement factor C4. This association with malignancy is not seen in juvenile DM and rarely if ever in polymyositis. A general physical examination, a thorough review of systems, a chest radiograph or computed tomography (CT), a mammogram (in women), a complete blood count (CBC), urinalysis, and stool guaiac, colonoscopy, Pap smears in women, and CT scan of abdomen and pelvis are considered a reasonable screening protocol.

Laboratory tests typically demonstrate the elevated CK. ANA and anti-Jo1 may be elevated. MRI usually shows inflammation in affected muscles. EMG will reveal characteristic myopathic changes in established disease. The characteristic histopathology in DM is perifascicular atrophy although this may not be seen in early disease (see Fig. 76-5). Inflammation is not prominent; when present it is seen in the perimysial and perivascular regions.

The pathogenesis of DM is thought to be a microangiopathy. A membrane attack complex (MAC) can be demonstrated on capillaries. Electron microscopy (EM) may reveal tubuloreticular inclusions in endothelial cells.

Treatment of Polymyositis and Dermatomyositis

Muscle disorders are best managed by considering disease-specific therapies, genetic counseling, and various forms of supportive care. Unfortunately, few specific pharmacologic therapies are currently available for the myopathies. Directed therapies are anticipated for a number of genetic disorders but are not yet available.

Inclusion Body Myositis

Clinical Vignette

A 74-year-old woman complained of progressive difficulty walking dating back the past 5 years. Recently she found it especially difficult to negotiate her stairs at home. She also reported several falls in the past 6 months, all of them due to “knee buckling and legs giving out.” Lately she had noted difficulty using her hands, especially when she needed to grip things firmly.

Neurologic examination revealed significant weakness of the finger flexors bilaterally; quadriceps weakness was also present—this was severe on the left and mild on the right. There was also mild weakness of the right wrist, ankle dorsiflexors, and neck flexors. Ankle jerks were diminished; the remainder of muscle stretch reflexes and sensory examination results were normal.

Serum CK was increased to 900 IU/L. Nerve conduction studies were normal. EMG revealed a mixed myopathic–neuropathic pattern of motor units with increased insertional activity and fibrillation potentials. Muscle biopsy of the left quadriceps demonstrated endomysial inflammation and atrophic and hypertrophic fibers. Rimmed vacuoles were identified with a modified Gomori trichrome stain. Electron microscopy revealed tubofilament inclusion bodies in affected fibers.

Inclusion body myositis is the most common inflammatory myopathy occurring in patients older than age 50. It is often an insidiously progressive condition often presenting after years of subtle symptoms. Men are more commonly affected. IBM is frequently characterized by the finding of an asymmetric weakness that typically affects the finger and wrist flexors in the upper extremities as well as quadriceps and tibialis anterior in the lower extremities. Dysphagia may also occur. An associated sensory neuropathy may occur in IBM patients. Usually there is no involvement of the other systems. Unlike that in PM or DM, there is no associated interstitial lung disease, myocarditis, or malignancy.

Laboratory tests reveal an elevated CK (usually three to six times normal). EMG will usually reveal myopathic findings although occasionally the clinical and EMG findings may be misinterpreted as being consistent with amyotrophic lateral sclerosis. However, the mixture of myopathic as well as neurogenic changes often provides a clue to the primary pathophysiology. Muscle biopsy demonstrates endomysial inflammation and the characteristic rimmed vacuoles, which may stain positive for amyloid, although sampling error may occur and the absence of rimmed vacuoles does not exclude the possibility of IBM. Intranuclear and intracytoplasmic tubulofilament inclusions are demonstrated by electron microscopy.

The precise pathogenesis of IBM is unknown. Muscle biopsy demonstrates a definite inflammatory component. However, despite therapeutic trials of a number of various immunosuppressive pharmacologic agents, none of the traditional immunomodulation therapies are beneficial.

The general prognosis for an IBM patient is of a slowly ingravescent course with various limitations, particularly due to finger flexor weakness, that impairs fine manipulations such as buttoning clothes, handwriting, and putting keys into locks. However, the overall affect on these patients is such that there is not an increased mortality rate; their major hazard relates to the potential for aspiration secondary to upper pharyngeal muscle involvement.

Other Acquired Myopathies

Toxic Myopathies

Many pharmacologic agents may cause myopathies as rare adverse effects of their use (Box 76-1). The almost ubiquitously utilized HMG–CoA reductase inhibitor (statin) class of lipid-lowering agents may cause a necrotizing myopathy in a small percentage of these patients. Muscle biopsies in severely affected patients demonstrate necrosis and mitochondrial changes.

More commonly, a slightly larger percentage develops an asymptomatic hyperCKemia. This is thought to be related to subclinical muscle inflammation. On other occasions, some patients taking statins present with myalgias, and/or proximal weakness. Very rarely a rhabdomyolysis may develop in this setting. The risk for muscle toxicity increases in patients simultaneously exposed to multiple potentially myotoxic drugs. Fibric acid derivatives and niacin also occasionally demonstrate myotoxic properties.

Chloroquine may cause an amphiphilic neuromyopathy. These patients classically demonstrate both a peripheral neuropathy and a myopathy. This combination is very typical for chloroquine per se and the physician always needs to inquire about the possibility of the patient utilizing this medication. The serum CK level is often modestly increased in this setting. Muscle biopsy characteristically reveals an autophagic vacuolation, with markedly increased staining for acid phosphatase.

Chronic administration of steroids, typically at doses higher than 30 g/day, can also cause a myopathy. Steroid myopathy can present acutely or subacutely, classically with preferential involvement of the proximal lower extremities. Bulbar and distal muscles, sensation, and reflexes are typically spared. Importantly, CK is normal. Nerve conduction and needle EMG are typically normal, and muscle biopsy may demonstrate atrophy of type II (especially IIB) fibers, lipid droplets within type I fibers, and rarely abnormal mitochondria on electron microscopy.

Amiodarone is an antiarrhythmic drug that causes a neuromyopathy similar to that produced by chloroquine. It can also cause myopathy indirectly, by inducing hypothyroidism.

Colchicine may also cause either a myopathy or neuropathy, which may be related to colchicine-induced alteration of microtubular function. CK is usually increased, and muscle biopsies demonstrate autophagic vacuoles. Symptoms improve with drug discontinuation.

Immunosuppressive agents including cyclosporine and Tacrolimus may cause generalized myalgias and proximal muscle weakness within months after starting therapy. The pathogenic basis for this effect is still unknown; there is some suggestion that cyclosporine myotoxicity may have a pathogenesis similar to that of statins. There is a further increased risk of developing a myopathy when patients take both cyclosporine and statins.

Labetalol is an antihypertensive drug that has been associated with rare reports of necrotizing myopathy. Symptoms improve after discontinuation of the drug.

Propofol is a relatively newer anesthetic agent increasingly used in sedating ventilated patients. There have been reports of rhabdomyolysis and myoglobinuria described in children, but not in adults. Vincristine, a chemotherapeutic agent, acts by disrupting the polymerization of tubulin into microtubules. It is classically associated with a severe sensorimotor axonal neuropathy, but occasionally it can also cause proximal muscle weakness accompanied by myalgias.

Zidovudine (AZT), a primary therapy for HIV infection, can induce a myopathy related to mitochondrial dysfunction. The myopathies caused by zidovudine and by HIV infection are clinically indistinguishable. CK values are usually increased. EMG does not distinguish between toxic AZT and HIV myopathies. Muscle biopsies demonstrate endomysial inflammation. Prominent ragged red fibers suggest AZT-induced mitochondrial abnormalities. AZT myopathies usually improve on drug cessation.

Hypokalemic Myopathies

Hypokalemia is a rare metabolic cause of an acute myopathy (Fig. 76-8). The presentation may mimic Guillain–Barré syndrome. ICU observation is recommended because of potential serious cardiac arrhythmias that the severe hypokalemia may induce. The differential diagnosis includes various potassium-losing diuretics and corticosteroids and other medications (e.g., laxatives, lithium, or amphotericin). Chronic alcoholism, rarely hyperaldosteronism or a villous adenoma of the colon, and very excessive intakes of licorice, are other important causes of hypokalemia-induced weakness.

Endocrine Myopathies

Clinical Vignette

A 41-year-old woman had typical myopathic symptoms. Her husband noted that her emotions were more labile. Neurologic examination demonstrated moderate proximal weakness. Serum CK was normal but the aldolase was mildly elevated. When she returned for her EMG, the neurologist noted generalized bruising that resembled that of patients taking corticosteroids, although neither was she taking same nor were there any apparent other common stigmata of Cushing syndrome. The patient’s EMG demonstrated myopathic motor unit potentials with fibrillation potentials.

Because of her obvious classic dermatologic stigmata, Cushing syndrome was considered in the differential of this slowly evolving myopathy. Serum cortisol and particularly urinary free cortisol levels as well as 24-hour 17-OH corticosteroids were increased. An endocrinologist also found historical evidence of easy bruising, and recent-onset hypertension; this exam demonstrated very mild increase in facial hair, slight mooning of her facies, but no abdominal striae or shoulder hump. Elevated ACTH levels led to the diagnosis of a corticotrophin-producing pituitary tumor.

Comment: This patient’s clinical picture was suggestive of a proximal myopathy and the easy bruising on examination led to the suspicion of Cushing syndrome. Clinically the typical features of Cushing syndrome were quite subtle. Her EMG findings were surprising because most endocrine myopathies, including corticosteroid-induced myopathies, are not associated with myopathic MUPs or abnormal insertional activity. Despite such, laboratory tests confirmed the diagnosis of Cushing disease.

Disorders of the adrenal, thyroid, parathyroid, and pituitary glands can result in subacute or, less commonly, acute myopathies. Interestingly, muscle involvement in such conditions may be apparent before patients develop typical clinical findings of their primary endocrinopathy. This is well illustrated by the prior vignette.

Cushing syndrome due to hyperadrenocorticism is either primary, iatrogenic, or rarely secondary to excessive pituitary secretion of ACTH (Fig. 76-9). This is one of the more common causes of an endocrine myopathy. Patients with Cushing syndrome, irrespective of etiology, experience proximal muscle weakness with atrophy usually starting in the hip girdles. Distal, bulbar, and ocular muscles are usually unaffected. Women seem to be more susceptible than men. Alternate-day corticosteroid dosing schedules and enriched protein diets may reduce susceptibility to iatrogenic induced Cushing syndrome. The serum CK level is usually normal. EMG is normal in iatrogenic steroid myopathy but is occasionally “myopathic” in patients with true Cushing syndrome. Muscle biopsy demonstrates a nonspecific type II muscle fiber atrophy. The pathogenesis of the myopathy is poorly understood but may be related to increased protein catabolism.

Primary adrenocortical insufficiency or Addison disease may be associated with a myopathy. Addison disease is characterized by weight loss, bronzing of the skin, hypotension, and hyperkalemia (see Fig. 76-9). Muscle weakness may be an early symptom of this disease and may be due to the associated hyperkalemia.

Thyroid dysfunction is another important consideration in the differential diagnosis of adult-onset myopathies. Hypothyroidism-associated myopathy is characterized by proximal weakness, fatigue, slowed movements and reflexes, stiffness, myalgia, and muscle cramps (Fig. 76-10). An elevated CK, sometimes up to 10 times normal, is a common finding in hypothyroid patients.

Hyperthyroidism-induced myopathy may also present with weakness, and the incidence of weakness in patients with thyrotoxicosis is high (up to 82%). Patients with thyrotoxicosis tend to have proximal muscle weakness and fatigue as prominent complaints (Fig. 76-11). Serum enzyme levels including CPK and AST tend to be normal.

In addition to typical myopathic features, hyperthyroid patients have brisk muscle stretch reflexes, thyroid eye disease with proptosis, and impairment of extraocular muscle function. Furthermore, myasthenia gravis occurs in approximately 5% of thyrotoxic patients. Asian males with hyperthyroidism also have a propensity to hypokalemic periodic paralysis. Serum CK and routine electrodiagnostic study results are usually normal.

Hyperparathyroidism may be associated with a painful myopathy. This most likely relates to an interchange with vitamin D metabolism and resultant osteomalacia.

Infectious Myopathies

Human immunodeficiency virus (HIV) infection may produce a primary inflammatory myopathy with subacute or chronic proximal weakness and myalgia. Typically seen in patients with CD4 counts of less than 200/mm3, HIV myopathy may be difficult to distinguish from polymyositis.

Nonspecific viral syndromes, particularly in relation to the enteric and influenza viruses, often cause significant myalgia in their prodromal phases. An acute relatively specific viral myositis occasionally occurs in children. It presents with prominent calf pain and toe walking. The CK level is usually increased; EMG may demonstrate myopathic changes, and muscle biopsy reveals scattered necrotic and regenerating fibers. The course is self-limiting. Rarely, there may be severe muscle rhabdomyolysis with significant increase of CK, myoglobinuria, and consequent metabolic derangement.

Trichinosis, typically caused by the ingestion of inadequately cooked pork, is the most common parasitic infection of muscle. Some patients have a prodrome of nausea, vomiting, and periorbital edema within days after exposure. Strikingly severe myalgia, weakness, fever, and sometimes encephalopathy then develop. Occasionally, trichinosis causes a chronic myopathy. Typically there is an associated eosinophilic leukocytosis. The serum CK level may be increased. Muscle biopsy sometimes demonstrates organisms and eosinophilic infiltration.

Pyomyositis is a rare primary bacterial infection characterized by a focal myopathy. This is primarily seen in the tropics. It is more common in immunodeficient individuals. A variety of gram-positive and -negative organisms have been associated with this. Muscle pain, tenderness, and fever are prominent. Neutrophilic leukocytosis and bacteremia also occur. CT and MRI of muscle may demonstrate muscle abscesses.

Treatment of Myopathies

Toxic myopathies and critical illness myopathy most commonly resolve within weeks to months of withdrawal of the offending agent. In this instance treatment is supportive, and most patients fully recover muscle strength.

The myotoxicity of cholesterol-lowering agents creates a common and vexing clinical problem. In some patients, CK increases and myalgia persist long after cholesterol-lowering agents are withdrawn. The basis for this phenomenon is unknown. However, recent evidence suggests that some people with statin myopathy are vitamin D deficient. Replacement of same while maintaining statin therapy leads to complete recovery in most of these individuals.

Endocrine myopathies are responsive to treatment of hormonal excess or deficiency. Corticosteroid-induced endocrine myopathies usually respond to cessation of steroid therapy or treatment of primary pituitary or adrenal lesions. Some infectious myopathies, such as trichinosis, may respond to antimicrobial agents, corticosteroids, or both. Treatment of pyomyositis consists of appropriate antibiotics and surgical drainage of abscesses.

Additional Resources

Ahmed W, Khan N, Glueck CJ, et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res. 2009 Jan;153(1):11-16.

Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry. 2009;80:1186-1193.

Amato AA, Russell JA. Neuromuscular Disorders. New York: McGraw-Hill; 2008.

Davies NP, Hanna MG. The skeletal muscle channelopathies: distinct entities and overlapping syndromes. Curr Opin Neurol. 2003;16:559-568.

DiMauro S, Lamperti C. Muscle glycogenoses. Muscle Nerve. 2001;24:984-999.

Engel AG. Metabolic and endocrine myopathies. In Walton NJ, editor: Disorders of voluntary muscle, 5th ed, Edinburgh: Churchill-Livingstone, 1988.

Engel AG, Banker BQ, editors. Myology. New York: McGraw-Hill, 1986.

Fardet L, Dupuy A, Gain M, et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore). 2009 Mar;88(2):91-97.

Felice KJ, Schneebaum AB, Jones HR. McArdle’s disease with late onset symptoms. J Neurol Neurosurg Psychiatry. 1992;55:407-408.

Ferrante MA, Wilbourn AJ. Myopathies. In: Levin KH, Luders HO, editors. Comprehensive Clinical Neurophysiology. Philadelphia, Pa: WB Saunders; 2000:268-281.

Griggs RC, Engel WK, Resnick JS. Acetazolamide treatment of periodic paralysis. Ann Int Med. 1970;73:39-48.

Griggs RC, Mendell JR, Miller RG. Evaluation and Treatment of Myopathy. Philadelphia, Pa: FA Davis Co; 1995.

Haller RG, Knochel JP. Metabolic myopathies. In: Johnson RT, Griffin JW, editors. Current Therapy in Neurologic Disease. St. Louis, Mo: Mosby-Year Book; 1993:397-402.

Jones HR, Darras B, De Vivo DC. Neuromuscular disorders of infancy, childhood, and adolescence: a clinician’s approach. Elsevier Health Sciences. 2002.

Katirji B, Al-Jaberi MM. Creatine kinase revisited. J Clin Neuromusc Dis. 2001;2:158-163.

McManis PG, Lambert EH, Daube JR. The exercise test in periodic paralysis. Muscle Nerve. 1986;8:704-710.

Miller A. Muscle disease. American Academy of Neurology. Continuum. Philadelphia, Pa: Lippincott Williams & Wilkins; 2006:12. No 3

Moxley RTIII. Channelopathies affecting skeletal muscle in childhood: myotonic disorders including myotonic dystrophy and periodic paralysis. In: Jones HR, De Vivo DC, Darras BT, editors. Neuromuscular Disorders of Infancy, Childhood, and Adolescence. Philadelphia, Pa: Butterworth-Heinemann; 2003:1017-1035.

Muthukrishnan J, Jha S, Modi KD, et al. Symptomatic primary hyperparathyroidism: a retrospective analysis of fifty one cases from a single centre. J Assoc Physicians India. 2008 Jul;56:503-507.

Al-Said YA, Al-Rached HS, Al-Qahtani HA, et al. Severe proximal myopathy with remarkable recovery after vitamin D treatment. Can J Neurol Sci. 2009 May;36(3):336-339.

Simmons A, Peterlin BL, Boyer PJ, et al. Muscle biopsy in the evaluation of patients with modestly elevated creatine kinase levels. Muscle Nerve. 2003;27:242-244.

Tonin P, Lewis P, Servidei S, et al. Metabolic causes of myoglobinuria. Ann Neurol. 1990;27:181-185.

Warren JD, Blumberg PC, Thompson PD. Rhabdomyolysis. Muscle Nerve. 2002;25:332-347.